DENVER, Colo.--(BUSINESS WIRE)--The Sorin Group (MIL:SRN), the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announced today that it received the U.S. Food and Drug Administration’s approval for marketing of its Mitroflow Aortic Pericardial Heart Valve in the USA.
Biological valves have become an increasingly viable option to replace native diseased valves since they are designed to improve patient quality of life by negating the need for lifelong anticoagulation therapy.
